QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by August, A. Articles by Cantorna, M. T. Search for Related Content PubMed PubMed Citation Articles by August, A. Articles by Cantorna, M. T. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Asthma

---

Symposium: Nutrients, Nuclear Receptors, Inflammation, and Immunity

Nutrients, Nuclear Receptors, Inflammation, Immunity Lipids, PPAR, and Allergic Asthma^1–3,

Avery August^*,,**,4, Cynthia Mueller^*,, Veronika Weaver, Tiffany A. Polanco^*,, Elizabeth R. Walsh^*,,** and Margherita T. Cantorna^*,**,

^* Center for Molecular Immunology and Infectious Disease, Department of Veterinary and Biomedical Science, ^** Pathobiology Graduate Program, and Department of Nutrition Science, The Pennsylvania State University, University Park, PA 16802

⁴ To whom correspondence should be addressed. E-mail: axa45{at}psu.edu.

The peroxisome proliferator-activated receptors (PPARs) belong to the larger superfamily of steroid/thyroid nuclear receptors. PPAR is expressed in a number of hematopoietic cells, including dendritic cells, eosinophils, macrophages, and T cells. A number of lipids and synthetic compounds interact with PPAR, that, depending on the cell type, results in the regulation of specific genes. There is now a large body of data indicating that allergic asthma is the result of a predominant type-2 helper T cell immune response including IL-4, -5 and -13, eosinophilic inflammation in the lungs, mucous production, and airway hyperresponsiveness (AHR). Targeting the production of these type-2 helper T cell mediated cytokines has been proposed as a way to regulate this disease. Because PPAR ligands can affect T cell cytokine production in vitro, we have examined whether these ligands affect symptoms of allergic asthma in a murine model of this disease. We discuss data showing that ciglitazone and GW1929, two agonistic ligands for PPAR, significantly inhibited airway inflammation during allergic asthma induction. Oral treatment with ciglitazone and GW1929 inhibited airway inflammation, with less of an effect on AHR. By contrast, intranasal exposure to GW1929 significantly reduced AHR following exposure to allergen, while GW9662, a PPAR antagonist, had no effect. In vitro, T cells from ciglitazone-treated mice secreted significantly less IL-4 and IFN- in response to restimulation. These data suggest that PPAR agonists may be useful for the treatment of allergic asthma.

KEY WORDS: • allergy • asthma • lung • PPAR • transcription factors

This article has been cited by other articles:

				J. E. Milam, V. G. Keshamouni, S. H. Phan, B. Hu, S. R. Gangireddy, C. M. Hogaboam, T. J. Standiford, V. J. Thannickal, and R. C. Reddy PPAR-{gamma} agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol, May 1, 2008; 294(5): L891 - L901. [Abstract] [Full Text] [PDF]

				C. J. Delvecchio, P. Bilan, K. Radford, J. Stephen, B. L. Trigatti, G. Cox, K. Parameswaran, and J. P. Capone Liver X Receptor Stimulates Cholesterol Efflux and Inhibits Expression of Proinflammatory Mediators in Human Airway Smooth Muscle Cells Mol. Endocrinol., June 1, 2007; 21(6): 1324 - 1334. [Abstract] [Full Text] [PDF]